General Information of Drug (ID: DMIY134)

Drug Name
ANA-04 Drug Info
Synonyms ANA-506; ANA-506); ANB-004; Human monoclonal antibody (inflammatory disease/autoimmune disease), AnaptysBio; Multi-specific antibody (autoimmune disease/inflammatory disease), AnaptysBio/VLST Corp
Indication
Disease Entry ICD 11 Status REF
Autoimmune diabetes 5A10 Investigative [1]
Cross-matching ID
TTD Drug ID
DMIY134

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Brodalumab DMASDQ6 Plaque psoriasis EA90.0 Approved [2]
CNTO-6785 DM6RQXB Rheumatoid arthritis FA20 Phase 2 [3]
CAT-2200 DMWHP52 Rheumatoid arthritis FA20 Investigative [1]
NI-1401 DMG9OBA Autoimmune diabetes 5A10 Investigative [1]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 17 receptor (IL17R) TT69OHW I17RA_HUMAN; I17RB_HUMAN; I17RC_HUMAN; I17RD_HUMAN; I17RE_HUMAN Not Available [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2294).
2 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)